{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:38:55Z","timestamp":1787009935549,"version":"build-2736575974"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To examine the association among tyrosine kinase inhibitor (TKI) out-of-pocket costs, adherence, and health care costs and utilization in a large group of commercially insured patients with chronic myeloid leukemia (CML).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Patients with CML aged 18 to 64 years were identified using IBM MarketScan Commercial Database between April 1, 2011 and December 31, 2014. Patients were required to be continuously enrolled 3 months before and 12 months after TKI (imatinib, dasatinib, or nilotinib) initiation. TKI adherence is estimated using the proportion of days covered (PDC), defined as the percentage of the PDC by the prescription fill during the 12-month study period (adherent patients have PDC \u226580%). Health care cost differences between adherent and nonadherent patients were estimated using generalized linear models. Health care utilization was compared using negative binomial regression models. All models were controlled for potential confounding factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The study sample consisted of 863 patients, where 355 (41.1%) patients were classified as adherent. Over the study period, nonadherent patients incurred US$10,974 more in medical costs (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001), and US$1663 more in non-TKI pharmacy costs (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.01). Adherent patients incurred US$28,184 more in TKI pharmacy costs (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001) that resulted in US$18,305 more in overall total health care costs (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). Adherent patients, however, were estimated to be less likely to have all-cause hospitalizations (incidence rate ratio, 0.32;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001), or CML-specific hospitalizations (incidence rate ratio, 0.31;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Patients with CML with better adherence experienced fewer hospitalizations, resulting in medical service cost savings. These lower medical costs, however, were more than offset by higher TKI medication costs observed during the first year of TKI therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/coc.0000000000000700","type":"journal-article","created":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T12:08:25Z","timestamp":1587211705000},"page":"517-525","source":"Crossref","is-referenced-by-count":11,"title":["Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia"],"prefix":"10.1097","volume":"43","author":[{"given":"Hsiao Ling","family":"Phuar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Begley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyaw","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudy Millard","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/1078155217710553","article-title":"BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia","volume":"24","author":"Cuellar","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.blre.2014.06.001","article-title":"Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia","volume":"28","author":"Mathisen","year":"2014","journal-title":"Blood Rev"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","volume":"121","year":"2013","journal-title":"Blood"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jama.298.1.61","article-title":"Prescription drug cost sharing: associations with medication and medical utilization and spending and health","volume":"298","author":"Goldman","year":"2007","journal-title":"JAMA"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s11606-007-0180-x","article-title":"Patients at-risk for cost-related medication nonadherence: a review of the literature","volume":"22","author":"Briesacher","year":"2007","journal-title":"J Gen Intern Med"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","article-title":"Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia","volume":"32","author":"Dusetzina","year":"2013","journal-title":"J Clin Oncol"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/archinternmed.2009.41","article-title":"Cost sharing and the initiation of drug therapy for the chronically ill\u2014invited commentary","volume":"169","author":"Majumdar","year":"2009","journal-title":"Arch Intern Med"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10549-010-0952-6","article-title":"Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer","volume":"125","author":"Sedjo","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3816\/CBC.2008.n.016","article-title":"Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer","volume":"8","author":"Kirk","year":"2008","journal-title":"Clin Breast Cancer"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1200\/JCO.2010.33.3179","article-title":"Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer","volume":"29","author":"Neugut","year":"2011","journal-title":"J Clin Oncol"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10865-005-2562-z","article-title":"Patient strategies to cope with high prescription medication costs: who is cutting back on necessities, increasing debt, or underusing medications?","volume":"28","author":"Heisler","year":"2005","journal-title":"J Behav Med"},{"issue":"3 suppl","key":"R26-20230903","doi-asserted-by":"crossref","first-page":"46s","DOI":"10.1200\/JOP.2011.000316","article-title":"Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions","volume":"7","author":"Streeter","year":"2011","journal-title":"J Oncol Pract"},{"key":"R29-20230903","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs","volume":"25","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"R30-20230903","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1185\/03007995.2014.991440","article-title":"Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs","volume":"31","author":"Ward","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"R31-20230903","first-page":"1140","article-title":"Tyrosine kinase inhibitors initiation, cost sharing, and health care utilization in patients with newly diagnosed chronic myeloid leukemia: a retrospective claims-based study","volume":"25","author":"Phuar","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"R35-20230903","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1475-6773.2008.00900.x","article-title":"What\u2019s the risk? A simple approach for estimating adjusted risk measures from nonlinear models including logistic regression","volume":"44","author":"Kleinman","year":"2009","journal-title":"Health Serv Res"},{"key":"R36-20230903","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/1536867X1301300304","article-title":"Computing adjusted risk ratios and risk differences in stata","volume":"13","author":"Norton","year":"2013","journal-title":"Stata J"},{"key":"R38-20230903","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2012.082511","article-title":"Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges","volume":"99","author":"Noens","year":"2014","journal-title":"Haematologica"},{"key":"R39-20230903","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000444626","article-title":"Medication adherence to tyrosine kinase inhibitors: 2-year analysis of medication adherence to imatinib treatment for chronic myeloid leukemia and correlation with the depth of molecular response","volume":"136","author":"Santoleri","year":"2016","journal-title":"Acta Haematol"},{"key":"R42-20230903","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clml.2012.04.002","article-title":"Adherence to BCR-ABL inhibitors: issues for CML therapy","volume":"12","author":"Jabbour","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R43-20230903","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.critrevonc.2015.08.025","article-title":"To adhere or not to adhere: rates and reasons of medication adherence in hematological cancer patients","volume":"97","author":"Hall","year":"2016","journal-title":"Crit Rev Oncol"},{"key":"R44-20230903","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clinthera.2014.10.019","article-title":"Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the united states","volume":"37","author":"Henk","year":"2015","journal-title":"Clin Ther"},{"key":"R45-20230903","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood.V114.22.2209.2209","article-title":"Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia","volume":"114","author":"StCharles","year":"2009","journal-title":"Blood"},{"key":"R46-20230903","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","article-title":"Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug imatinib as prescribed","volume":"35","author":"Eliasson","year":"2011","journal-title":"Leuk Res"},{"key":"R47-20230903","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.leukres.2013.07.003","article-title":"Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors","volume":"38","author":"Efficace","year":"2014","journal-title":"Leuk Res"},{"key":"R48-20230903","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/03007990903396469","article-title":"Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"R49-20230903","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/j.clml.2015.07.647","article-title":"Economic burden of tyrosine kinase inhibitor treatment failure in chronic myeloid leukemia","volume":"15","author":"Knopf","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R50-20230903","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1185\/03007995.2015.1120189","article-title":"Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia","volume":"32","author":"McGarry","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"R51-20230903","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1185\/03007995.2010.533648","article-title":"Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"R52-20230903","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/94.9.652","article-title":"Adherence to therapy with oral antineoplastic agents","volume":"94","author":"Partridge","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R53-20230903","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3322\/caac.20004","article-title":"Patient adherence and persistence with oral anticancer treatment","volume":"59","author":"Ruddy","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"R54-20230903","first-page":"S272","article-title":"Coverage and use of cancer therapies in the treatment of chronic myeloid leukemia","volume":"18","author":"Darkow","year":"2012","journal-title":"Am J Manag Care"},{"key":"R55-20230903","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3109\/10428194.2015.1088654","article-title":"Healthcare utilization and costs associated with tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia","volume":"57","author":"Kropf","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"R56-20230903","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol"},{"key":"R57-20230903","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ajh.23180","article-title":"Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia","volume":"87","author":"Jabbour","year":"2012","journal-title":"Am J Hematol"},{"key":"R58-20230903","first-page":"214","article-title":"Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency","volume":"23","author":"Latremouille-Viau","year":"2017","journal-title":"J Manag Care Spec Pharm"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T00:04:24Z","timestamp":1693699464000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000700"}},"subtitle":["A Retrospective Claims-Based Study"],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000700","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,16]]}}}